Interferons (IFNs) play a major role in the control of hepatitis B virus (HBV), whether as endogenous cytokines limiting the spread of the virus during the acute phase of the infection or as drugs for the treatment of its chronic phase. However, the mechanism by which IFNs inhibit HBV replication has so far remained elusive. Here, we show that type I and II IFN treatment of human hepatocytes induces the production of APOBEC3G (A3G) and, to a lesser extent, that of APOBEC3F (A3F) and APOBEC3B (A3B) but not that of two other cytidine deaminases also endowed with anti-HBV activity, activation-induced cytidine deaminase (AID), and APOBEC1. Most importantly, we reveal that blocking A3B, A3F, and A3G by combining RNA interference and the virion infectivity factor (Vif) protein of human immunodeficiency virus does not abrogate the inhibitory effect of IFNs on HBV. We conclude that these cytidine deaminases are not essential effectors of IFN in its action against this pathogen.More than 350 millions individuals worldwide suffer from chronic hepatitis B virus (HBV) infection (66), a condition that evolves towards liver insufficiency and hepatocellular carcinoma in approximately 15 to 40% of cases (31). However, the majority of de novo HBV infections, except for those occurring during the perinatal period, are cleared during the acute phase. This appears to result largely from noncytopathic host defense mechanisms involving cytokines, most notably interferons (IFNs) (2, 21). A key role for IFN in the biology of HBV infection is further illustrated by studies in animal models of the disease. For instance, HBV-specific T cells from acutely infected chimpanzees produce high levels of gamma IFN (IFN-␥) coincident with viral clearance (23,37). Also, the induction of alpha/beta IFN (IFN-␣/) or the production of IFN-␥ by transferred HBV-specific cytotoxic T lymphocytes inhibits HBV replication in the liver of HBV transgenic mice (9,19,20,35). Finally, IFN-␣ is the standard treatment for chronic hepatitis B (17). Although type I and II IFNs are the most important immune regulators of HBV replication, the downstream effectors mediating the inhibitory action of IFN on HBV replication have not yet been identified.